Table 3 Comparison of Ki-67 and tumour size in pCR and non-pCR patients.

From: Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study

 

Patients with pCR

Patients with non-pCR

P value

n

Mean

SD

(Q1, median, Q3)

n

Mean

SD

(Q1, median, Q3)

Interim Ki-67 index

58

18.8

16.9

(10.0, 19.7, 30.0)

94

22.6

16.8

(5.3, 14.3, 25.6)

0.064‡

Ki-67 reduction rate (%)

57

64.6

28.2

(31.2, 59.8, 76.5)

94

49.6

40.3

(47.2, 71.1, 83.3)

0.0058‡

Interim tumour size (cm)*

52

2.2

1.3

(1.5, 2.0, 3.0)

80

2.9

1.7

(1.9, 2.5, 3.6)

0.015†

Tumour size reduction rate (%)

50

45.1

26.2

(33.3, 40.0, 54.0)

79

30.9

25.3

(12.5, 28.6, 42.9)

0.0027†

  1. pCR pathological complete response, SD standard deviation, Q1 1st quartile, Q3 3rd quartile.
  2. *Determined by palpation. †Wilcoxon test. ‡T test.
Back to article page